Drug
Plerixafor clinical trials
Also written Mozobil, AMD3100 and JM-3100.
- studies test it
- 121
- open now
- 8
- in phase 3
- 6
- first study started
- 2004
Keep track of what changes. Save the plerixafor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
120 studies that test it; most in 2010 (20)
| Year | Studies |
|---|---|
| 2004 | 8 |
| 2005 | 5 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 20 |
| 2011 | 11 |
| 2012 | 7 |
| 2013 | 8 |
| 2014 | 11 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 50
- Phase 2
- 76
- Phase 3
- 6
- Phase 4
- 5
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
- Leukemia
- 10
Who runs them
Industry 29 · Other 92
Genzyme, a Sanofi Company (20) · Washington University School of Medicine (8) · St. Jude Children's Research Hospital (5) · National Heart, Lung, and Blood Institute (NHLBI) (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · M.D. Anderson Cancer Center (5) · Fred Hutchinson Cancer Center (4) · Sanofi (3)
Often tested with
Tested in the same studies.
Filgrastim (37) · Granulocyte Colony-Stimulating Factor (24) · Cytarabine (5) · Busulfan (5) · Cyclophosphamide (4) · Sirolimus (4) · Etoposide (4) · Alemtuzumab (3)
Studies
Open first, then newest update. How each study uses plerixafor is read from its arms, and is right about nine times in ten.
Testing it · 121
- Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT07775313Written as Plerixafor
- Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine ModelsRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02015013Written as Plerixafor
- Stem Cell Mobilization and Apheresis for Life-threatening Blood DisordersRecruitingPhase 1St. Jude Children's Research HospitalNCT07585136Written as Plerixafor
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06325709Written as Plerixafor
- Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet DisorderRecruitingPhase 1M.D. Anderson Cancer CenterNCT06414889Written as Plerixafor
- Allo HSCT for High Risk HemoglobinopathiesRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT06872333Written as Plerixafor (mozobil)
- Mozobil for Autologous Hematopoietic Stem Cell TransplantationRecruitingPhase 2Thomas Jefferson UniversityNCT07188090Written as Plerixafor
- Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal EndometriumRecruitingEarly Phase 1Hugh TaylorNCT05343572Written as Plerixafor
- A Phase I Study of Mozobil in the Treatment of Patients With WHIMSCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00967785Written as Mozobil (TM)
- Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell DiseaseActive, not recruitingPhase 1City of Hope Medical CenterNCT03664830Written as Plerixafor
- Reduced Intensity Transplantation for Severe Sickle Cell DiseaseActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT04362293Written as hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
- Plerixafor Versus G-CSF in the Treatment of People With WHIM SyndromeCompletedPhase 2/3National Institute of Allergy and Infectious Diseases (NIAID)NCT02231879Written as Plerixafor
- Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-ThalassemiaActive, not recruitingPhase 1/2National Heart, Lung, and Blood Institute (NHLBI)NCT05357482Written as Plerixafor
- Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT02570542Written as Plerixafor
- Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With GlioblastomaCompletedPhase 2Lawrence D RechtNCT03746080Written as Plerixafor
- Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma PatientsCompletedPhase 4SanofiNCT05087212Written as plerixafor + G-CSF
- A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell DiseaseCompletedPhase 1/2Sangamo TherapeuticsNCT03653247Written as Plerixafor
- Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and PlerixaforCompletedPhase 1/2Assistance Publique - Hôpitaux de ParisNCT02678533Written as Plerixafor
- Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell PatientsCompletedPhase 1/2Assistance Publique - Hôpitaux de ParisNCT02212535Written as Plerixafor
- Study of MGTA-145 and Plerixafor in Patients With Sickle Cell DiseaseTerminatedPhase 2EnsomaNCT05445128Written as Plerixafor
See all 121 studies that test plerixafor →
Given in every arm · 22 — plerixafor is usual care beside what is tested
- Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...RecruitingPhase 1/2National Cancer Institute (NCI)NCT05470491Written as Plerixafor
- Gene Editing For Sickle Cell DiseaseRecruitingPhase 1St. Jude Children's Research HospitalNCT06506461Written as Plerixafor
- Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07605416Written as Plerixafor
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple MyelomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06207799Written as Plerixafor
- Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGDRecruitingPhase 2IRCCS San RaffaeleNCT03055247Written as Mozobil
- Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin LymphomaActive, not recruitingPhase 1/2City of Hope Medical CenterNCT01318317Written as Plerixafor
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted GraftActive, not recruitingPhase 1Stanford UniversityNCT05088356Written as Plerixafor
- Stem Cell Transplantation for Patients With Multiple MyelomaCompletedPhase 1University of ChicagoNCT01526096Written as Plerixafor
- Scleroderma Treatment With Autologous Transplant (STAT) StudyCompletedPhase 2Fred Hutchinson Cancer CenterNCT01413100Written as Plerixafor
- Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced CancerTerminatedPhase 1Jonsson Comprehensive Cancer CenterNCT03240861Written as Plerixafor
- CHOEP + High Dose Therapy + Auto SCT for T-Cell LymphomaTerminatedPhase 2Dana-Farber Cancer InstituteNCT01746173Written as Plerixafor
- A Dose Finding Study of CycloSam® Combined With External Beam RadiotherapyWithdrawnPhase 1Albert Einstein College of MedicineNCT03612466Written as Mozobil
- O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant GliomasTerminatedPhase 1/2Fred Hutchinson Cancer CenterNCT00669669Written as Plerixafor
- Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)CompletedPhase 2Siddhartha GangulyNCT02703779Written as Mozobil
- TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple MyelomaWithdrawnPhase 1Jonsson Comprehensive Cancer CenterNCT03506802Written as Plerixafor
- Quantitating the Impact of PlerixaforStatus unknownPhase 1/2E. Steve WoodleNCT02522572Written as plerixafor
- Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple MyelomaCompletedPhase 1/2Dana-Farber Cancer InstituteNCT00903968Written as Plerixafor
- Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade GliomaTerminatedPhase 1Patrick Y. Wen, MDNCT01339039Written as Plerixafor
- Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin LymphomaCompletedPhase 2Washington University School of MedicineNCT02098109Written as Plerixafor
- Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)CompletedPhase 1GlaxoSmithKlineNCT01802892Written as Plerixafor
Showing 20 of 22.
As the comparator · 1 — what is tested is compared with plerixafor
Codes
What other systems call plerixafor · ClinicalTrials.gg INT003795
- MeSH (NLM) C088327plerixaforConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) S915P5499NPLERIXAFORConfirmed FDA, NLM, Wikidata
- RxNorm 733003Confirmed FDA, Wikidata
- Wikidata Q905835plerixaforConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1777PlerixaforOne source FDA
- DrugBank DB06809One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C088327 | plerixafor | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | S915P5499N | PLERIXAFOR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 733003 | — | Confirmed FDA, Wikidata |
| Wikidata | Q905835 | plerixafor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1777 | Plerixafor | One source FDA |
| DrugBank | DB06809 | — | One source Wikidata |
Also registered as amd-3329 (UNII 3EUZ070LLN), plerixafor octahydrobromide (UNII S79I522MQB) and plerixafor octahydrochloride (UNII OD49913540).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.